mercredi 4 janvier 2012

3 sociétés israéliennes parmi les '2011 best 18 deals list du NY Times'

Source: Globes 

Teva, Makhteshim and Fundtech featured in the newspaper's "Deal Professor A's" for the best deal makers of the year.

Three Israeli deals made "The New York Times" list of the best deals in 2011. The paper cited 18 deals for its "Deal Professor A’s" for the best deals and deal makers of the year.
The acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE: TEVA). "The New York Times" says, "Teva made a quick strike to buy Cephalon for $6.8 billion after a hostile bidder, Valeant Pharmaceuticals, opened up the opportunity. Teva showed the value of opportunistic and quick action in deal-making, winning the Bruce Wasserstein “Dare to Be Great” award."

The acquisition of Makhteshim Agan Industries Ltd. by China National Chemical Corporation (ChemChina). "ChemChina, in partnership with Koor Industries Ltd. (TASE:KOR) of Israel, buys 60% of an Israeli agricultural chemical company, Makhteshim. The deal, valued at $2.4 billion, was one of the largest outbound investments by China ever, and showed that the country was on the prowl internationally for crucial suppliers. In light of American efforts to block many Chinese deals on national security grounds, Chinese money is being directed elsewhere.
The Fundtech-GTCR merger, and the parallel merger of rival S1 Corporation (Nasdaq: SONE) with ACI Worldwide Inc (Nasdaq: ACIW). "The New York Times" says, "S1 and Fundtech had agreed to combine in a stock-for-stock merger valued at about $318 million. Each soon received its own unsolicited offer to be acquired. S1 and Fundtech terminated their deal, with S1 being acquired by ACI and Fundtech going to GTCR. The deals showed the rare ability of a bidder to top a stock-for-stock deal and not only disrupt it but end up on the winning end."
Published by Globes [online], Israel business news - - on January 4, 2012

Aucun commentaire :